Aviation Stock Flyte (NYSE American: $VTAK) Partners with Blade to Supercharge Vision Jet Distribution and Regional Air Mobility Reach; @flyflyte

Aviation Stock Flyte (NYSE American: $VTAK) Partners with Blade to Supercharge Vision Jet Distribution and Regional Air Mobility Reach; @flyflyte

 

 

 

Investorideas.com Newswire)   Investorideas.com, a trusted leader in publishing investing ideas for over 25 years issues news for aviation stock  Catheter Precision, Inc. (NYSE American: VTAK). 

 

Fly Flyte, Inc. , the Regional Air Mobility subsidiary of Catheter Precision, Inc. (NYSE American: VTAK), today announced a strategic partnership with Blade Urban Air Mobility (“Blade”) designed to expand customer reach, increase booking opportunities, improve aircraft utilization, and accelerate awareness of the Flyte platform among premium aviation travelers.

 

Key News Points

Flyte's Vision Jet Fleet to Be Featured on Blade Platform, Expanding Distribution across One of the Industry's Leading Air Mobility Networks

Strategic Partnership Expected to Increase Aircraft Utilization, Customer Acquisition, Brand Awareness, and Platform-Driven Revenue Opportunities

Strategic Relationship Further Validates Flyte's Regional Air Mobility Model and Expands Reach into Blade's Ecosystem

 

Under the partnership, Flyte's Cirrus Vision Jet fleet and charter offerings will be featured on Blade's platform, providing Blade passengers with access to a modern, efficient, and cost-effective private aviation solution for regional travel.

 

The partnership is expected to expand Flyte's visibility among a large and highly targeted audience of premium aviation consumers already utilizing technology-enabled air mobility solutions.

 

Flyte believes its Cirrus Vision Jet fleet is uniquely positioned to complement Blade's customer base, which has historically focused on premium, time-sensitive regional travel solutions.

 

Paid News Dissemination on behalf of VTAK

 

Read this news featuring VTAK in full at https://www.investorideas.com/news/2026/main/07213-vtak-flyte-blade-partnership-vision-jet.asp  

 

"We're excited to partner with Blade and make Flyte's Vision Jet fleet available through one of the industry's most recognized aviation platforms," said Marc Sellouk, Founder and CEO of Flyte. "This relationship broadens our distribution, introduces Flyte to a wider customer base, and represents another important step in executing our long-term growth strategy."

 

The Cirrus Vision Jet offers a differentiated private aviation experience featuring advanced safety technologies, including the Cirrus Airframe Parachute System (CAPS) and Safe Return Emergency Autoland, making it one of the most technologically advanced aircraft operating within the regional aviation marketplace.

 

Flyte continues to execute on its strategy of building a scalable regional air mobility platform through strategic partnerships, fleet expansion, technology integration, and increased consumer awareness initiatives. The company believes partnerships with established aviation brands can help accelerate growth while expanding access to premium travel customers throughout the United States.

 

The agreement is non-exclusive and subject to the terms and conditions of the parties' agreement.

 

About Flyte

Flyte is a private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient short-haul travel throughout the United States. Through fixed pricing, online booking, and a technology-enabled operating platform, Flyte delivers a faster, safer, and more convenient alternative to traditional private charter travel.

Flight operations are conducted through Flyte's wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier.

For more information, visit www.flyflyte.com.

 

About Blade Urban Air Mobility

Blade is the leading helicopter passenger service in the world with operations in the United States and Europe. The Company’s asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, will enable a seamless transition from helicopters and fixed-wing aircraft to Joby’s Electric Vertical Aircraft (“EVA” or “eVTOL”), enabling lower cost air mobility that is both quiet and emission-free.

 

For more information, visit www.blade.com.

 

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The company focuses on bringing new technologies to market through collaboration with physicians and continuous product innovation.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “focus,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our belief Flyte is uniquely positioned to expand fleet operations, enter new markets, and scale nationally, our belief our capital initiatives position the Company as a more streamlined public company with significant exposure to the rapidly expanding regional aviation market, the belief that FLYTE’s platform operational foundation allows for rapid fleet growth and expansion into additional high-demand regional markets and our belief the acquisition of Flyte, combined with recently secured institutional capital, provides the foundation for a focused, high-growth aviation strategy while also enabling the Company to simplify its balance sheet and streamline legacy operations. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether because of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K and Form 10-Q’s, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.

 

CONTACTS

Media Relations for Flyte
flyte@elev8newmedia.com

 

About Investorideas.com – where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Disclaimer/Disclosure:  This news featuring (NYSE: VTAK) is part of a paid for news publishing and content creation service at Investorideas.com. More payment details and disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

This article was originally posted on Investorideas.com https://www.investorideas.com/news/2026/main/07213-vtak-flyte-blade-partnership-vision-jet.asp

 

 

 

 

 

 

 

 

VisionWave Holdings (NASDAQ: $VWAV) Strengthens IP Portfolio with Provisional Patent on SkyWeave AI-Orchestrated Resilient Communication Platform; @VWAVInc

 

VisionWave Holdings (NASDAQ: $VWAV) Strengthens IP Portfolio with Provisional Patent on SkyWeave AI-Orchestrated Resilient Communication Platform; @VWAVInc

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV), a defense technology company developing advanced AI-powered defense, security and autonomous systems.

 

VisionWave Holdings, Inc. (NASDAQ: VWAV) today announced the filing of a U.S. provisional patent application covering SkyWeave™, an intelligent high-frequency communication ecosystem designed to enable resilient, long-range communication in satellite-denied, infrastructure-denied, and globally distributed operating environments.

 

The filing, titled “SkyWeave Intelligent HF Communicator: AI-Orchestrated Satellite-Free Global Communication Ecosystem,” was submitted as U.S. Provisional Application No. 64/103,289. The application was received by the United States Patent and Trademark Office on July 1, 2026, under attorney docket number 90000-600.

 

SkyWeave is designed to transform traditional HF communication into a more intelligent, automated, and mission-accessible communication capability. The system applies artificial intelligence, adaptive software logic, propagation analysis, intelligent listening, global recipient search, and dynamic communication control to help users establish communication across long distances without relying on satellites, cellular networks, or conventional terrestrial infrastructure.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/07141-visionwave-vwav-skyweave-provisional-patent-communication.asp

 

Unlike conventional HF systems that often require specialized operator knowledge, manual frequency planning, or fixed network assumptions, SkyWeave is conceived as an AI-orchestrated communication platform. A user may select a destination, region, coordinate, recipient ID, group ID, emergency authority, or mission node, and the system can assist in determining how, when, and through which communication path to attempt contact. This includes analysis of ionospheric conditions, frequency selection, antenna readiness, power state, message priority, security state, receiver availability, and link probability.

 

The invention is intended to support both defense and civil applications. In defense environments, SkyWeave may provide an important communication layer for operations where satellite links are unavailable, jammed, degraded, contested, or intentionally avoided. The system may support unmanned ground vehicles, including platforms such as VisionWave’s VARAN™ UGV, by enabling low-infrastructure command, status reporting, emergency signaling, relay-assisted communication, and mission coordination beyond ordinary line-of-sight communication limits. SkyWeave may also support drones, robotic systems, maritime assets, expeditionary forces, border-security operations, remote sensors, tactical teams, and distributed command networks.

 

VisionWave believes the potential value may be its integration into unmanned systems.  UGVs and drones often operate in locations where conventional communication may be intermittent, terrain-blocked, jammed, or dependent on vulnerable infrastructure. SkyWeave is intended to provide an adaptive communication method that can supplement existing radios, satellite links, mesh networks, and tactical data links. In certain embodiments, the system may select lower-data-rate waveforms, delayed transmission, relay mode, Global Search, or emergency packet formats when conditions degrade, thereby helping autonomous or semi-autonomous assets remain connected, report status, or request recovery support.

 

SkyWeave may also relevant to emergency services, disaster response, maritime safety, aviation backup communication, search-and-rescue, and personnel recovery. In a civil emergency, such as wildfire, earthquake, hurricane, flood, or infrastructure outage, SkyWeave may assist emergency responders and command centers by providing a communication option that does not depend on cellular towers or satellite availability. In maritime environments, it may support long-range distress signaling, vessel coordination, and backup communication. In aviation and personnel recovery scenarios, it may support airman rescue workflows, personal locator devices, emergency broadcasts, UAS-assisted search, rescue authority coordination, and authenticated distress signaling.

 

SkyWeave is designed to make complex HF communication more accessible. The system may include an Earth-map interface, AI-based path prediction, skip-zone and dead-zone visualization, recipient-oriented Global Search, Intelligent Listening Protocol, power-aware optimization, secure identity-based messaging, and a simplified “Communication Enabled” control. These capabilities are designed to reduce operator burden while improving the probability of successful communication under difficult conditions.

 

The provisional filing also describes scalable deployment embodiments. SkyWeave may be implemented as a handheld communicator, manpack system, vehicle-mounted unit, maritime communicator, aircraft module, drone module, fixed station, command-center node, or emergency shelter system. This flexibility allows the same core communication intelligence to be adapted across defense, civil, rescue, industrial, maritime, aviation, and humanitarian use cases.

 

“SkyWeave is designed to address a major operational challenge: how to communicate when satellites, cellular systems, and traditional infrastructure are unavailable or unreliable,” said Danny Rittman, first named inventor. “The goal is to make long-range HF communication smarter, more adaptive, and easier to use, while supporting both human operators and autonomous systems operating in contested or remote environments.”

 

The provisional application reflects VisionWave’s broader focus on resilient autonomy, intelligent sensing, AI-assisted decision systems, and mission-critical communication. SkyWeave is intended to complement VisionWave’s defense and autonomous platform ecosystem by providing an additional layer of communication resilience for unmanned vehicles, robotic systems, emergency response networks, and distributed field operations.

 

VisionWave is currently preparing a non-provisional patent application for SkyWeave, which it expects to file in the coming months.

 

The filing of a provisional patent application does not indicate issuance of a patent, and the scope of any future patent protection will depend on subsequent filings and examination. However, the application establishes a priority date for the subject matter disclosed in the application relating to SkyWeave’s AI-orchestrated, satellite-free global communication architecture.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company's website is https://www.vwav.inc

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the potential capabilities, applications, development path, market opportunity, and future commercialization of SkyWeave™ and related technologies, and the Company’s intention to file a non-provisional patent application. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to, risks related to the development, integration, and testing of advanced AI, HF communication, RF, and autonomous systems technologies; intellectual property prosecution, protection, and enforcement risks, including the risk that a provisional patent application may not result in the filing of a non-provisional application or the issuance of any patent; delays or failures in achieving technical, development, or commercialization milestones; regulatory, spectrum, export control, and national security approval requirements; market acceptance and competition; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

 

Contact: investors@vwav.inc

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 

 

 

Aethlon Medical (Nasdaq: $AEMD) Reports Consistent Directional Changes in Second Cohort of Australian Hemopurifier Oncology Trial

 

Aethlon Medical (Nasdaq: $AEMD) Reports Consistent Directional Changes in Second Cohort of Australian Hemopurifier Oncology Trial

Second cohort findings consistent with previously reported observations; an independent statistical analysis is planned following completion of all three patient cohorts

 

 

 

Investorideas.com (www.investorideas.com newswire), a leading investing news platform and biotech-stock research destination, features clinical-stage medical technology company and Investorideas.com featured stock Aethlon Medical, Inc. (Nasdaq: AEMD).

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first cohort following treatment with the investigational Hemopurifier(R). Replicating these findings in a second group of patients strengthens the scientific rationale for the Company's ongoing clinical program and supports continued enrollment in the third and final cohort before an independent statistical analysis is conducted.

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/07131-aethlon-aemd-second-cohort-hemopurifier-oncology.asp

 

"We are encouraged to observe similar directional changes across multiple biomarkers in both the first and second patient cohorts," said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Observing these directional changes in a second patient cohort builds upon our initial observations and provides additional data as we advance toward completion of the third cohort. While these are preliminary findings from an early feasibility study, they represent an important milestone as we advance toward completion of the third cohort and an independent statistical analysis to determine whether these observations represent a dose-response to Hemopurifier treatment."

The Australian feasibility study is evaluating the safety, feasibility and dosing of the Hemopurifier(R) in patients with advanced solid tumors whose cancers have progressed despite treatment with anti-PD-1 immunotherapies.

The second cohort continued to show directional changes in several biomarkers that researchers believe are associated with tumor growth, immune suppression and response to immunotherapy, including:

Reductions in tumor-derived extracellular vesicles (EVs), platelet-derived EVs and PD-L1-positive EVs, with these changes appearing more consistently across all participants than in the first cohort and generally persisting through the eight-week follow-up period.

Reductions in two microRNAs that have been associated with tumor growth and cancer invasion.

Improvements in multiple immune-related laboratory ratios - including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), Systemic Immune-Inflammation Index (SII), monocyte-to-albumin ratio (MAR) and Lymphocyte Albumin Index (LAI) - that have been associated in published research with improved responses to immunotherapy.

Increases in total T cells, CD4 and CD8 T-cell populations, and tumor-specific CD137-positive T cells in all three participants, with these changes generally persisting through the eight-week follow-up period.

Taken together, the first two cohorts have now shown similar directional changes across multiple biological markers following Hemopurifier treatment. Enrollment in the third cohort is underway, with the first participant having already completed three four-hour Hemopurifier treatments during a one-week period. After all three cohorts are complete, an independent statistician will analyze the combined data to determine whether these observations support a dose-response relationship.

EVs continue to be recognized as important drivers of cancer progression and resistance to checkpoint inhibitors such as Keytruda(R) and Opdivo(R). The Hemopurifier(R) is designed to remove these tumor-derived vesicles from the bloodstream, with the goal of reducing immune suppression and potentially enhancing the body's ability to fight cancer.

"We believe the Hemopurifier has the ability to complement existing therapies rather than replace them and could be a platform technology with potential applications across multiple disease areas such as oncology, infectious diseases, and future emerging threats. We believe there exists a 'pipeline within a single device,'" said Mr. Frakes.

Advancing a Novel Approach to Cancer Immunotherapy

Extracellular vesicles released by tumors continue to be recognized as important drivers of cancer progression, metastasis and resistance to immunotherapy. EVs expressing PD-L1 have been associated with resistance to checkpoint inhibitors, including Keytruda(R) and Opdivo(R). The Hemopurifier is designed to remove tumor-derived EVs and other pathogenic particles from circulation, potentially reducing immunosuppressive signaling and improving the body's anti-tumor immune response.

The Hemopurifier has received FDA Breakthrough Device Designation for the treatment of patients with advanced or metastatic cancer who are unresponsive or intolerant to standard-of-care therapy, as well as for the treatment of life-threatening viral infections not addressed by approved therapies.

Important Study Limitations

The Company cautions that these findings represent descriptive observations from raw data generated in an early-stage feasibility study. Formal statistical analyses have not yet been performed and will be conducted only after completion of all three study cohorts by an independent statistician.

The study was not designed to demonstrate clinical efficacy, and no conclusions can be drawn regarding the Hemopurifier's impact on patient outcomes. Larger, adequately powered clinical trials designed with clinical efficacy endpoints will be required to determine whether the biological changes observed translate into meaningful clinical benefit.

Aethlon Medical, Inc. (Nasdaq: AEMD)  is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

 

About Aethlon Medical

Aethlon Medical, Inc. is developing the Hemopurifier(R), an investigational extracorporeal therapeutic designed to remove tumor-derived extracellular vesicles and enveloped viruses from the bloodstream. The Company is advancing the Hemopurifier in oncology and life-threatening viral infections with the goal of improving outcomes for patients with limited treatment options.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," or similar expressions constitute forward-looking statements. Such forward looking statements include but are not limited to statements regarding the completion and timing of enrollment in the third cohort of the Australian oncology feasibility study; the timing and results of the independent statistical analysis; whether the biological changes observed following Hemopurifier(R) treatment are reproducible or support a dose-response relationship; the potential safety, feasibility or biological activity of the Hemopurifier; the ability of the Hemopurifier to remove tumor-derived extracellular vesicles or otherwise modulate immune function; whether the biological changes observed will translate into meaningful clinical benefit or improved patient outcomes; the potential for the Hemopurifier to complement existing cancer therapies or improve responses to immunotherapy; the future development, regulatory progress, clinical evaluation, commercialization or market acceptance of the Hemopurifier; the potential applicability of the Hemopurifier in oncology, viral infections or other disease indications; and the Company's plans, expectations and objectives for future clinical studies and development activities. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. The clinical findings described herein are preliminary in nature, have not been subjected to formal statistical analysis, and may not be replicated in subsequent clinical studies or trials.

Company Contact:

Jim Frakes

Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

Research biotech stocks at Investorideas.com:

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

 

 

 

 

Disclaimer/Disclosure: Aethlon Medical, Inc. is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

 

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

 

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411

 

 

AI Defense Stock VisionWave Holdings (NASDAQ: $VWAV) Shares Gain on News of Strategic Partnership with Former UK MP Ben Everitt’s Stratonex @VWAVInc

 

AI Defense Stock VisionWave Holdings (NASDAQ: $VWAV) Shares Gain on News of Strategic Partnership with Former UK MP Ben Everitt’s Stratonex @VWAVInc

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV), a defense technology company developing advanced AI-powered defense, security and autonomous systems.

 

VisionWave Holdings, Inc. (NASDAQ: VWAV) announced this morning that it has entered into a strategic Distributor Agreement with Stratonex Defence Technologies Ltd., a United Kingdom-based defense technology company co-founded by former Member of Parliament Ben Everitt.

 

The stock is trading up on the news, currently at 4.3400 +0.2800 (+6.90%) with a day’s high of 4.4199. Other AI defense stocks are seeing gains today including Palantir Technologies Inc. (Nasdaq: PLTR)\ trading at 129.66 +3.92 (+3.12%) as of this report.

Under the agreement, Stratonex will serve as VisionWave’s strategic commercialization, integration and sovereign delivery partner for the United Kingdom, Europe and other mutually agreed markets. The collaboration is designed to expand VisionWave’s commercial reach into defense, homeland security and government sectors by leveraging Stratonex’s experience, strategic relationships and understanding of the UK and European defense markets.

 

The agreement establishes a framework for identifying, developing and supporting commercial opportunities involving VisionWave’s growing portfolio of defense technologies, including autonomous systems, AI-enabled platforms, advanced sensing technologies, tactical communications, counter-drone solutions and related mission systems. Under the agreement, registered opportunities accepted by VisionWave will receive opportunity protection in accordance with the terms of the agreement.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/07022-visionwave-vwav-shares-gain-stratonex-partnership.asp

 

Douglas Davis, Chief Executive Officer of VisionWave, commented:

“The United Kingdom and Europe continue to make significant investments in defense modernization, autonomous technologies and next-generation battlefield capabilities. Establishing Stratonex as our strategic commercialization and sovereign delivery partner represents another important milestone in VisionWave’s international growth strategy.

Ben Everitt brings an exceptional combination of government, defense policy and strategic leadership experience, together with deep experience across the UK and European defense sectors. We believe Stratonex is well positioned to help introduce VisionWave’s expanding portfolio of technologies to government, defense and industrial customers throughout the region.”

 

Ben Everitt, Co-Founder of Stratonex Defence Technologies, commented:

“VisionWave has assembled an impressive portfolio of technologies addressing many of today’s most significant defense and homeland security challenges. We look forward to working with governments, defense organizations and industry partners throughout the United Kingdom and Europe to support the responsible deployment of these technologies while meeting sovereign capability and integration requirements.”

Mr. Everitt served as a Member of the Parliament of the United Kingdom from 2019 through 2024. He brings experience spanning government, public policy, international business and technology commercialization. Mr. Everitt also serves as a member of VisionWave’s Advisory Board; he is an independent advisor and is not a director, officer or employee of VisionWave.

 

The Distributor Agreement establishes a long-term commercial framework under which Stratonex will support business development, customer engagement, opportunity management, sovereign integration and commercialization of VisionWave technologies within the agreed territories. The agreement does not require minimum purchase commitments and future sales will be subject to individual customer contracts and purchase orders. There can be no assurance that the Distributor Agreement will result in any particular level of orders, revenue or commercial success. Additional information regarding the Distributor Agreement is set forth in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

 

Full news

https://www.investorideas.com/CO/VWAV/news/2026/07021-visionwave-stratonex-uk-europe-distributor-agreement.asp

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire.Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas